The A-share weight loss drug sector rose in the short term, with Livzon Group hitting the daily limit, Kangyuan Pharmaceutical rising more than 7%, Aimei and Borri Pharmaceutical rising more than 6%, and Hanyu Pharmaceutical and Sichuan Shuangma following suit. On the news front, the World Health Organization said that new guidelines for the treatment of adult obesity based on GLP-1 therapy are scheduled to be officially released in September.